JPRN-UMIN000030158
Completed
未知
Effect of Empagliflozin versus placebo on cardiac sympathetic activity in acute myocardial infarction patients with type 2 diabetes mellitus: Multi-Center placebo-controlled Double-Blind Randomized Trial - Effect of Empagliflozin versus placebo on cardiac sympathetic activity in acute myocardial infarction patients with type 2 diabetes mellitus: Multi-Center placebo-controlled Double-Blind Randomized Trial -EMBODY trial
ippon Medical School Hospital0 sites98 target enrollmentDecember 1, 2017
Overview
- Phase
- 未知
- Intervention
- Not specified
- Conditions
- Type 2 diabetes with acute myocardial infarction
- Sponsor
- ippon Medical School Hospital
- Enrollment
- 98
- Status
- Completed
- Last Updated
- 2 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- Not provided
Exclusion Criteria
- •1\) Type 1 diabetes mellitus 2\) Persistent atrial fibrillation 3\) Insulin, glucagon\-like peptide\-1 analogue, or other SGLT2 inhibitors user 4\) High dose of sulfonylurea (glimepiride \> 2 mg, glibenclamide \> 1\.25 mg, gliclazide \> 40 mg) 5\) HbA1c \>\= 10% 6\) History of diabetic ketoacidosis or diabetic coma within 3 months prior to the randomization 7\) Renal dysfunction (eGFR \< 45 mL/min/1\.73m2\) 8\) Heart failure graded at NYHA functional class IV 9\) Pregnancy or possible pregnancy and breast feeding 10\) Lack of informed consent 11\) Patients judged by the investigator to be ineligible for inclusion in this study 12\) Contraindicated for administration of empagliflozin
Outcomes
Primary Outcomes
Not specified
Similar Trials
Not yet recruiting
Phase 2
Efficacy of Empagliflozin on cardiac function in non- diabetic patients after primary percutaneous angioplasty on left anterior descending coronary arteryacute myocardial infarction.121-09IRCT20200727048226N1Tehran University of Medical Sciences88
Active, not recruiting
Phase 1
Impact of Empagliflozin on heart in patients with myocardial infarctioMyocardial infarctionTherapeutic area: Diseases [C] - Cardiovascular Diseases [C14]EUCTR2016-004591-22-ATMedical University of Graz/Department of Internal Medicine/Division of Endocrinology and Diabetology476
Active, not recruiting
Phase 1
Effect of Empagliflozin on Cardiac Output in Patients with Acute Heart Failure (EMPA Acute Heart Failure)EUCTR2017-002695-45-DERWTH Aachen University represented by the Rector, himself, represented by the Dean of the Medical Faculty50
Active, not recruiting
Phase 1
Effects of empagliflozin on cardiac remodeling and myocardial sympathetic nervous system in diabetic patients affected by chronic heart failurediabetes mellitus and heart failureMedDRA version: 20.0Level: LLTClassification code 10011949Term: Decompensation cardiacSystem Organ Class: 100000004849Therapeutic area: Diseases [C] - Cardiovascular Diseases [C14]EUCTR2019-002202-43-ITAOU FEDERICO II34
Active, not recruiting
Phase 1
Effect of Empagliflozin and Semaglutide on the Cardiovascular system and Kidneys in patients with type 2 diabetes – A randomized TrialType 2 Diabetes MellitusMedDRA version: 20.1Level: LLTClassification code 10045242Term: Type II diabetes mellitusSystem Organ Class: 100000004861Therapeutic area: Diseases [C] - Hormonal diseases [C19]EUCTR2019-000781-38-DKAarhus University Hospital120